<p>Biodesix, Inc.（NASDAQ:BDSX - 獲取免費報告）的股票在覆蓋該股票的六家券商中獲得了 “適度買入” 的共識評級，MarketBeat.com 報道。一位分析師給予該股票賣出評級，一位給予持有評級，四位則對該公司給予買入評級。在過去一年中，對該股票發佈評級的分析師的平均一年價格目標為 32.50 美元。</p>
<p>幾位分析師對 BDSX 股票進行了評論。Weiss Ratings 在 12 月 15 日的研究報告中重申了對 Biodesix 股票的 “賣出（e+）” 評級。Canaccord Genuity Group 在 9 月 19 日的報告中設定了 Biodesix 的 20.00 美元價格目標，並給予該股票 “買入” 評級。最後，華爾街禪在 11 月 8 日的研究報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。</p>
<p><strong>查看我們對 Biodesix 的最新分析</strong></p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者和對沖基金最近調整了對 BDSX 的持股。Birchview Capital LP 在第一季度將其在 Biodesix 的持股增加了 2.8%。Birchview Capital LP 目前擁有 5,736,113 股該公司的股票，價值 3,586,000 美元，此前在上個季度增持了 154,937 股。XTX Topco Ltd 在第二季度將其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 目前擁有 205,647 股該公司的股票，價值 58,000 美元，此前在上個季度增持了 102,494 股。Oracle Investment Management Inc. 在第三季度購買了 Biodesix 的新股份，價值 113,000 美元。最後，Millennium Management LLC 在第三季度收購了 Biodesix 的新股份，價值 113,000 美元。機構投資者和對沖基金持有該公司 20.96% 的股票。</p>
<h2>Biodesix 股票下跌 5.8%</h2>
<p>BDSX 股票週一開盤價為 6.69 美元。該公司的市值為 5325 萬美元，市盈率為 -1.20，貝塔值為 0.62。該公司的流動比率為 1.84，速動比率為 1.84，債務股本比率為 41.11。該公司的 50 日移動平均價格為 7.41 美元，200 日移動平均價格為 7.33 美元。Biodesix 的 12 個月低點為 3.44 美元，12 個月高點為 32.20 美元。</p>
<p>Biodesix（NASDAQ:BDSX - 獲取免費報告）最近於 11 月 3 日發佈了季度財報。該公司報告的每股收益（EPS）為（1.16）美元，超出市場共識預期的（1.60）美元，超出幅度為 0.44 美元。該公司本季度的收入為 2177 萬美元，而分析師的預期為 2098 萬美元。Biodesix 的淨利潤率為負的 49.31%，股本回報率為負的 504.41%。研究分析師預測，Biodesix 在當前財政年度的每股收益將為 -0.35。</p>
<h2>關於 Biodesix</h2>
<p>（獲取免費報告）</p>
<p>Biodesix, Inc 是一家總部位於科羅拉多州博爾德的商業階段分子診斷公司，開發和提供基於血液的檢測，以改善肺部疾病（包括肺癌）的診斷和管理。該公司整合了先進的蛋白質組學和最近的基因組技術，提供旨在指導臨牀決策的非侵入性檢測解決方案。Biodesix 運營着一家 CLIA 認證和 CAP 認可的實驗室，能夠大規模處理患者樣本並保持嚴格的質量標準。</p>
<p>該公司的旗艦產品 VeriStrat® 是一種蛋白質組學檢測，將非小細胞肺癌患者分層為更可能從特定療法中受益的組別。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>我不應該把這個發給你</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>黃金警報</li>
<li>比特幣下跌，但你的收入即將暴漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
<p>在你考慮 Biodesix 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Biodesix 並不在名單上。</p>
<p>雖然 Biodesix 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BDSX

<p>Biodesix, Inc.（納斯達克代碼：BDSX）獲得了六家券商的共識 “適度買入” 評級。該股票有一個賣出評級、一個持有評級和四個買入評級，平均一年目標價為 32.50 美元。機構投資者已調整其持股，其中 Birchview Capital LP 和 XTX Topco Ltd.的增持尤為顯著。Biodesix 的股票開盤價為 6.69 美元，市值為 5325 萬美元。該公司報告了上個季度超出預期的收益。Biodesix 專注於針對肺部疾病（包括肺癌）的血液檢測</p>

<p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus rating of &#34;Moderate Buy&#34; from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $32.50.</p>
<div class="lb-trans"><p>Biodesix, Inc.（NASDAQ:BDSX - 獲取免費報告）的股票在覆蓋該股票的六家券商中獲得了 “適度買入” 的共識評級，MarketBeat.com 報道。一位分析師給予該股票賣出評級，一位給予持有評級，四位則對該公司給予買入評級。在過去一年中，對該股票發佈評級的分析師的平均一年價格目標為 32.50 美元。</p>
</div><p>Several analysts have commented on BDSX shares. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Monday, December 15th. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the stock a &#34;buy&#34; rating in a report on Friday, September 19th. Finally, Wall Street Zen raised Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th.</p>
<div class="lb-trans"><p>幾位分析師對 BDSX 股票進行了評論。Weiss Ratings 在 12 月 15 日的研究報告中重申了對 Biodesix 股票的 “賣出（e+）” 評級。Canaccord Genuity Group 在 9 月 19 日的報告中設定了 Biodesix 的 20.00 美元價格目標，並給予該股票 “買入” 評級。最後，華爾街禪在 11 月 8 日的研究報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。</p>
</div><p><strong>Check Out Our Latest Analysis on Biodesix</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Biodesix 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of BDSX. Birchview Capital LP increased its position in shares of Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock worth $3,586,000 after acquiring an additional 154,937 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new stake in Biodesix in the 3rd quarter valued at $113,000. Institutional investors and hedge funds own 20.96% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近調整了對 BDSX 的持股。Birchview Capital LP 在第一季度將其在 Biodesix 的持股增加了 2.8%。Birchview Capital LP 目前擁有 5,736,113 股該公司的股票，價值 3,586,000 美元，此前在上個季度增持了 154,937 股。XTX Topco Ltd 在第二季度將其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 目前擁有 205,647 股該公司的股票，價值 58,000 美元，此前在上個季度增持了 102,494 股。Oracle Investment Management Inc. 在第三季度購買了 Biodesix 的新股份，價值 113,000 美元。最後，Millennium Management LLC 在第三季度收購了 Biodesix 的新股份，價值 113,000 美元。機構投資者和對沖基金持有該公司 20.96% 的股票。</p>
</div><h2>Biodesix Trading Down 5.8%</h2>
<div class="lb-trans"><h2>Biodesix 股票下跌 5.8%</h2>
</div><p>Shares of BDSX stock opened at $6.69 on Monday. The company has a market capitalization of $53.25 million, a price-to-earnings ratio of -1.20 and a beta of 0.62. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The firm has a 50-day moving average price of $7.41 and a 200 day moving average price of $7.33. Biodesix has a twelve month low of $3.44 and a twelve month high of $32.20.</p>
<div class="lb-trans"><p>BDSX 股票週一開盤價為 6.69 美元。該公司的市值為 5325 萬美元，市盈率為 -1.20，貝塔值為 0.62。該公司的流動比率為 1.84，速動比率為 1.84，債務股本比率為 41.11。該公司的 50 日移動平均價格為 7.41 美元，200 日移動平均價格為 7.33 美元。Biodesix 的 12 個月低點為 3.44 美元，12 個月高點為 32.20 美元。</p>
</div><p>Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.60) by $0.44. The company had revenue of $21.77 million for the quarter, compared to analysts' expectations of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Research analysts forecast that Biodesix will post -0.35 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Biodesix（NASDAQ:BDSX - 獲取免費報告）最近於 11 月 3 日發佈了季度財報。該公司報告的每股收益（EPS）為（1.16）美元，超出市場共識預期的（1.60）美元，超出幅度為 0.44 美元。該公司本季度的收入為 2177 萬美元，而分析師的預期為 2098 萬美元。Biodesix 的淨利潤率為負的 49.31%，股本回報率為負的 504.41%。研究分析師預測，Biodesix 在當前財政年度的每股收益將為 -0.35。</p>
</div><h2>About Biodesix</h2>
<div class="lb-trans"><h2>關於 Biodesix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.</p>
<div class="lb-trans"><p>Biodesix, Inc 是一家總部位於科羅拉多州博爾德的商業階段分子診斷公司，開發和提供基於血液的檢測，以改善肺部疾病（包括肺癌）的診斷和管理。該公司整合了先進的蛋白質組學和最近的基因組技術，提供旨在指導臨牀決策的非侵入性檢測解決方案。Biodesix 運營着一家 CLIA 認證和 CAP 認可的實驗室，能夠大規模處理患者樣本並保持嚴格的質量標準。</p>
</div><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p>
<div class="lb-trans"><p>該公司的旗艦產品 VeriStrat® 是一種蛋白質組學檢測，將非小細胞肺癌患者分層為更可能從特定療法中受益的組別。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>I Shouldn't Be Sending You This</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>GOLD ALERT</li>
<li>Bitcoin is down but your income is about to explode</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>我不應該把這個發給你</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>黃金警報</li>
<li>比特幣下跌，但你的收入即將暴漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Biodesix 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Biodesix 並不在名單上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Biodesix 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Biodesix, Inc.（NASDAQ:BDSX）被券商給予 “適度買入” 的平均評級